We are Kojic Acid Dipalmitate CAS:79725-98-7 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
CAS No: 79725-98-7
Product Name: Kojic Acid Dipalmitate
Kojic Acid Dipalmitate
Density: 1.0±0.1 g/cm3
Boiling Point: 684.7±55.0 °C at 760 mmHg
Melting Point: 92-96ºC
Molecular Formula: C38H66O6
Molecular Weight: 618.927
Flash Point: 273.9±31.5 °C
Exact Mass: 618.485962
Vapour Pressure: 0.0±2.1 mmHg at 25°C
Index of Refraction: 1.492
Appearance: White sheet crystal
Loss on drying: ≤0.5%
Ignition residue: ≤0.5%
Color reaction of ferric chloride: Negative
Heaby metal: ≤10ppm
Applicationd in cosmetic whitening additives.
It can be mixed with cream and lotion type cosmetics to make curative and whitening cosmetics with good curative effect on age spots, freckles and pigmentation.
Kojic acid dipalmitate is an improved kojic acid derivative, which overcomes the instability of kojic acid to light, heat and metal ions, and also maintains kojic acid's inhibition of tyrosinase activity and blocks skin melanin formation Effect, and this inhibition is stronger than kojic acid, making it a new generation of highly effective whitening active agent. As a fat-soluble whitening active agent, kojic acid dipalmitate can be more easily absorbed by the skin in addition to being easier to formulate, and at the same time bring good moisturizing effect to the skin.
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Related News: This is how an API becomes a medicine.6-cloro-2-metil-3-nitropiridina CAS:22280-60-0 This is how an API becomes a medicine.2-Fluoro-3-methylaniline CAS:1978-33-2 This is how an API becomes a medicine.1-(4-Hydrazinophenyl)methyl-1,2,4-triazole At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival.At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival.